# Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

> **NCT02383251** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 118 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02383251
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-15
- **Primary completion:** 2019-08
- **Final completion:** 2020-12-31
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383251, "Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02383251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*